[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2018000298A1 - Anticuerpos anti-cd154 y métodos de uso de estos. - Google Patents

Anticuerpos anti-cd154 y métodos de uso de estos.

Info

Publication number
CL2018000298A1
CL2018000298A1 CL2018000298A CL2018000298A CL2018000298A1 CL 2018000298 A1 CL2018000298 A1 CL 2018000298A1 CL 2018000298 A CL2018000298 A CL 2018000298A CL 2018000298 A CL2018000298 A CL 2018000298A CL 2018000298 A1 CL2018000298 A1 CL 2018000298A1
Authority
CL
Chile
Prior art keywords
antibodies
methods
polinucleotides
codify
fragments
Prior art date
Application number
CL2018000298A
Other languages
English (en)
Inventor
Alexey Teplyakov
Galina Obmolova
Johan Fransson
Jocelyn Leu
Anish Suri
Fang Teng
Hong Zhou
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CL2018000298A1 publication Critical patent/CL2018000298A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A LOS ANTICUERPOS ANTAGONISTAS QUE SE UNEN ESPECÍFICAMENTE A CD154, LOS POLINUCLEÓTIDOS QUE CODIFICAN LOS ANTICUERPOS O FRAGMENTOS, Y LOS MÉTODOS DE PREPARACIÓN Y LOS USOS DE ESTOS.</p>
CL2018000298A 2015-08-05 2018-02-01 Anticuerpos anti-cd154 y métodos de uso de estos. CL2018000298A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562201150P 2015-08-05 2015-08-05
US201662367660P 2016-07-28 2016-07-28

Publications (1)

Publication Number Publication Date
CL2018000298A1 true CL2018000298A1 (es) 2018-05-11

Family

ID=57944010

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000298A CL2018000298A1 (es) 2015-08-05 2018-02-01 Anticuerpos anti-cd154 y métodos de uso de estos.

Country Status (26)

Country Link
US (2) US10669343B2 (es)
EP (1) EP3331563B1 (es)
JP (2) JP7049988B2 (es)
KR (1) KR20180030917A (es)
CN (2) CN107921128B (es)
AU (1) AU2016301361B2 (es)
BR (1) BR112018002319A2 (es)
CA (1) CA2994825A1 (es)
CL (1) CL2018000298A1 (es)
CO (1) CO2018001256A2 (es)
EA (1) EA201890434A1 (es)
EC (1) ECSP18008922A (es)
ES (1) ES2944982T3 (es)
GT (1) GT201800034A (es)
HK (1) HK1256804A1 (es)
IL (2) IL293065A (es)
MA (1) MA45573A (es)
MX (1) MX2018001522A (es)
MY (1) MY188405A (es)
NI (1) NI201800017A (es)
PE (1) PE20180802A1 (es)
PH (1) PH12018500203A1 (es)
SG (1) SG10201913275QA (es)
SV (1) SV2018005624A (es)
UA (1) UA123398C2 (es)
WO (1) WO2017024146A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11248055B2 (en) 2015-11-27 2022-02-15 Ablynx N.V. Polypeptides inhibiting CD40L

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10457698B2 (en) 2015-08-05 2019-10-29 Eisai R&D Management Co., Ltd Chiral reagents for preparation of substituted phosphorodiamidate morpholino oligomers
PE20180802A1 (es) * 2015-08-05 2018-05-09 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos
US20210317220A1 (en) * 2018-09-24 2021-10-14 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd154 antibody
CA3145453A1 (en) * 2019-07-01 2021-01-07 Tonix Pharma Limited Anti-cd154 antibodies and uses thereof
JP2022540187A (ja) * 2019-07-08 2022-09-14 プロジェン・カンパニー・リミテッド 新規融合タンパク質及びその用途
US20230078330A1 (en) * 2020-01-27 2023-03-16 Vanderbilt University Human anti-dengue antibodies and methods of use therefor
IL299942A (en) * 2020-07-28 2023-03-01 Lg Chemical Ltd Anti-LILRB1 antibody and its uses
CN115586338A (zh) * 2022-09-20 2023-01-10 杭州赛基生物科技有限公司 用于检测可溶性细胞因子受体的试剂盒及其制备方法
WO2024222895A1 (zh) * 2023-04-28 2024-10-31 信达生物制药(苏州)有限公司 抗cd40l抗体及其在人自身免疫疾病治疗的应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541606A (en) 1895-06-25 Sealed package
US226A (en) 1837-06-03 Samuel goss
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
KR100283541B1 (ko) 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
DK0672141T3 (da) 1992-10-23 2003-06-10 Immunex Corp Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
CN1137726C (zh) 1993-09-02 2004-02-11 达特茅斯学院理事 延长体液免疫抑制的方法
WO1995006666A1 (en) 1993-09-02 1995-03-09 Trustees Of Dartmouth College Anti-gp39 antibodies and uses therefor
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
DE69631331T2 (de) 1995-06-07 2004-11-18 Immunex Corp., Seattle Cd40l mutein
CN1173878A (zh) 1995-10-16 1998-02-18 尤尼利弗公司 双功能或双价抗体片段类似物
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
NL1003537C2 (nl) 1996-07-08 1998-01-12 Holland Railconsult B V Werkwijze voor het vervaardigen van een gebogen beglazing.
WO1998052606A1 (en) 1997-05-17 1998-11-26 Biogen, Inc. Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
KR20010072564A (ko) 1998-04-03 2001-07-31 존 에프. 카바나프 루푸스 및 관련된 신장 질환의 치료 및/또는 반전에사용되는 안티 ｇｐ39 항체의 용도
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
GB9915653D0 (en) 1999-07-06 1999-09-01 Bruce Terry Hose clamp
EP1221973B1 (en) 1999-10-04 2007-05-30 Novartis Vaccines and Diagnostics, Inc. CD40 antagonist for treating psoriasis
ATE344801T1 (de) 1999-12-29 2006-11-15 Immunogen Inc Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
KR20120090094A (ko) 2003-06-13 2012-08-16 바이오겐 아이덱 엠에이 인코포레이티드 아글리코실 항-ｃｄ154(ｃｄ40 리간드) 항체 및 이의 용도
EP3120861B1 (en) 2003-11-06 2018-08-15 Seattle Genetics, Inc. Intermediate for conjugate preparation comprising auristatin derivatives and a linker
WO2006033702A2 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
WO2006125201A2 (en) 2005-05-19 2006-11-23 Centocor, Inc. Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
US8114964B2 (en) 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
EP2097170A4 (en) 2006-11-20 2010-04-07 Nanostellar Inc PROCESS FOR PRODUCING HETEROGENEOUS CATALYSTS CONTAINING METAL NANOPARTICLES
BRPI0809042B1 (pt) 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
JP5681482B2 (ja) 2007-03-29 2015-03-11 ゲンマブ エー／エス 二重特異性抗体およびその作製方法
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
MX350962B (es) 2008-01-07 2017-09-27 Amgen Inc Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20100261620A1 (en) 2008-10-14 2010-10-14 Juan Carlos Almagro Methods of Humanizing and Affinity-Maturing Antibodies
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP2506871B1 (en) 2009-11-30 2016-10-19 Janssen Biotech, Inc. ANTIBODY Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
US8795950B2 (en) 2010-06-30 2014-08-05 Jonghan Choi Method of improving print performance in flexographic printing plates
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
EP2444101A1 (en) 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
US20140121123A1 (en) 2010-10-29 2014-05-01 Kevin Caili Wang Methods for diversifying antibodies, antibodies derived therefrom and uses thereof
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
SG191233A1 (en) 2010-12-23 2013-07-31 Janssen Biotech Inc Active protease-resistant antibody fc mutants
CN103649118A (zh) * 2011-03-01 2014-03-19 安进公司 双特异性结合剂
US8852597B2 (en) 2011-04-04 2014-10-07 The Trustees Of Dartmouth College Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
ES2819075T3 (es) 2011-10-11 2021-04-14 Viela Bio Inc Matrices de soporte derivadas de TN3 específicas para CD40L y sus métodos de empleo
KR101637915B1 (ko) 2011-10-13 2016-07-11 브리스톨-마이어스 스큅 컴퍼니 Cd40l을 길항하는 항체 폴리펩티드
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
EP3653049B1 (en) 2012-12-14 2023-09-13 OmniAb, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
PE20180802A1 (es) * 2015-08-05 2018-05-09 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos
US10651781B2 (en) 2017-08-24 2020-05-12 Corning Incorporated Glass roof shingle

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11248055B2 (en) 2015-11-27 2022-02-15 Ablynx N.V. Polypeptides inhibiting CD40L

Also Published As

Publication number Publication date
KR20180030917A (ko) 2018-03-26
MX2018001522A (es) 2018-03-15
PH12018500203A1 (en) 2018-07-30
ECSP18008922A (es) 2018-04-30
JP7049988B2 (ja) 2022-04-07
SV2018005624A (es) 2018-09-25
ES2944982T3 (es) 2023-06-27
EP3331563A1 (en) 2018-06-13
SG10201913275QA (en) 2020-02-27
CO2018001256A2 (es) 2018-05-10
CN114605549A (zh) 2022-06-10
MA45573A (fr) 2019-05-15
IL293065A (en) 2022-07-01
AU2016301361A1 (en) 2018-02-08
EA201890434A1 (ru) 2018-10-31
JP2018522562A (ja) 2018-08-16
HK1256804A1 (zh) 2019-10-04
NZ739597A (en) 2021-03-26
MY188405A (en) 2021-12-08
JP2022058414A (ja) 2022-04-12
IL256997A (en) 2018-03-29
EP3331563B1 (en) 2023-04-19
GT201800034A (es) 2019-09-26
US11421037B2 (en) 2022-08-23
CA2994825A1 (en) 2017-02-09
US20200317794A1 (en) 2020-10-08
EP3331563A4 (en) 2019-09-04
CN107921128B (zh) 2022-04-26
PE20180802A1 (es) 2018-05-09
CN107921128A (zh) 2018-04-17
BR112018002319A2 (pt) 2018-12-11
AU2016301361B2 (en) 2022-06-16
NI201800017A (es) 2018-08-24
US20170037136A1 (en) 2017-02-09
US10669343B2 (en) 2020-06-02
UA123398C2 (uk) 2021-03-31
WO2017024146A1 (en) 2017-02-09
IL256997B (en) 2022-06-01

Similar Documents

Publication Publication Date Title
CL2018000298A1 (es) Anticuerpos anti-cd154 y métodos de uso de estos.
SV2018005659A (es) Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CL2018000479A1 (es) Linfoopeitina strimal tomica (tslp) - anticuerpos de union y metodos de uso de los anticuerpos
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
DOP2019000165A (es) Anticuerpos anti-ox40 y sus usos
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CL2016002156A1 (es) Anticuerpo que une erbb-2 y erbb-3
CL2017001461A1 (es) Composiciones y métodos para anticuerpos que se marcan bmp6
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
CL2018000819A1 (es) Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
BR112016030968A2 (pt) análogos de pridopidina, preparação e uso destes
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
BR112017006232A2 (pt) processos e intermediários na preparação de antagonistas de c5ar
CL2017002596A1 (es) Neutralización del virus chikungunya mediada por anticuerpos